We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.’s share was trading at $27.02 as of February 19th. ZBIO’s trailing P/E was 1.93 according to Yahoo Finance.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. ZBIO is transitioning from a pre-revenue stage to commercialization, with analysts projecting revenues to rise from near zero to $30 million in 2026 and significant growth thereafter. Its lead asset, obexelimab, targets IgG4-Related Disease (IgG4-RD), a market with no approved therapies, offering a rare at-home treatment option that avoids B-cell depletion and reduces infection risk.
This unique mechanism via CD19/FcγRIIb preserves patients’ immune systems and represents a potential competitive moat, though January 2026 trial data indicated efficacy may fall short of “best-in-class” expectations, highlighting the binary nature of regulatory and commercial success. Beyond IgG4-RD, obexelimab is being tested in Warm Autoimmune Hemolytic Anemia and Multiple Sclerosis, positioning Zenas for a long-term role in B-cell-mediated autoimmune diseases. CEO Lonnie Moulder, founder of TESARO, has cultivated a culture of “Capital Efficient Innovation,” though rapid growth and recent stock volatility, including a 50% drop in January 2026, pose risks to talent retention.
Zenas entered 2026 with ~$270 million in cash, supporting operations through 2028, and has expanded its pipeline via in-licensing strategies, mitigating early-stage discovery risk. While early commercialization will incur high marginal costs, the potential sale of obexelimab at scale offers highly asymmetric upside, particularly if the drug becomes the global standard of care or validates its multi-indication potential.
Current market focus on hazard ratio metrics underestimates long-term value, leaving ZBIO trading at a significant discount to potential. With flawless execution on regulatory filings and commercialization, Zenas could achieve a market capitalization up to five times its current value, making it an attractive, high-risk, high-reward investment opportunity.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG CRSP by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, partnership with Vertex, and a broader gene-editing pipeline. CRSP’s stock price has appreciated by approximately 33.65% since our coverage. Danny Green shares a similar view but emphasizes Zenas BioPharma ZBIO’s pre-revenue to commercialization transition and obexelimab’s potential in IgG4-RD and other autoimmune diseases.
Zenas BioPharma, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge fund portfolios held ZBIO at the end of the third quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of ZBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZBIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
